Q-omics provides the consensus-scored GNRH2 profile across patient tissues and cancer cell-line models. GNRH2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GNRH2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, GNRH2 RNA expression shows 15,137 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where GNRH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNRH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNRH2 survival associations across molecular data types. GNRH2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNRH2 RNA expression–survival associations across cancer types. High GNRH2 expression shows unfavorable associations in KIRC, DLBC, ACC, LGG and UVM, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GNRH2 RNA expression.
This table summarizes GNRH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GNRH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNRH2 shows lower tumor expression in THCA, KIRC, KICH and KIRP and higher tumor expression in COAD and HNSC. The THCA box plot shows higher GNRH2 RNA expression in normal versus tumor tissue (log2 FC = −0.898, t-test p < 0.001).
This table shows molecular features associated with GNRH2 in patient tissues and cancer cell lines. In patient samples, GNRH2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNRH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
